Experimental drug cocktail aims to outsmart childhood cancers
NCT ID NCT04308330
First seen Apr 23, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This early-phase trial tests a four-drug combination—vorinostat plus three chemotherapy drugs—in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goal is to find the safest dose of vorinostat when used with the other drugs, and to see what side effects occur. Up to 30 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Medical College
RECRUITINGValhalla, New York, 10595, United States
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vorinostat (Zolinza) combined with vincristine, irinotecan, and temozolomide
What this could lead to
If it works, this could point toward a new treatment option for children and young adults with hard-to-treat cancers that have come back or not responded to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, focused on finding a safe dose. The combination may not shrink tumors or could cause severe side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.